– FRANCE, Strasbourg – Transgene (Euronext Paris:TNG), a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, announced the new composition of its board of directors and the appointment of new statutory auditors following yesterday’s annual shareholders’ meeting (AGM).

The AGM appointed Mr Antoine Béret1 as an independent director, to replace Mr Arnaud Fayet who did not seek a renewal of his term.

“We warmly thank Arnaud Fayet who has accompanied us since 2000, including as chairman of our audit committee. His strong professional skills, his availability, his open mindset and his human qualities have been precious to us over the course of these years,” said Philippe Archinard, Chairman and CEO of Transgene. He added: “We are pleased to welcome Antoine Béret. He brings us decades of experience in creating and directing businesses in our industry and we look forward to benefiting from them over the next steps of our development.”

In addition, the AGM has

  • renewed the mandates of Mr Jean-Luc Bélingard and three independent directors: Prof. Laurence Zitvogel, MD, Jean-Pierre Bizzari, MD, and Mr Jean-François Labbé. The board of directors is composed of 10 members, including six independent directors;
  • renewed the mandates of Ernst et Young & Autres and Auditex as primary and substitute statutory auditors respectively and appointed two new statutory auditors: Grant Thornton (primary) and IGEC company (substitute);
  • voted the other resolutions submitted, in accordance with the recommendations of the Board of Directors.

About Transgene

Transgene S.A. (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>

Comments are closed.